Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.
1. A method of inhibiting the urge to urinate in an adult human subject over an interval of about two hours to no more than about eight hours while reducing the risk that the human subject develops hyponatremia, comprising administering to an adult human subject in need thereof a formulation consisting of an effective, low dose amount of desmopressin and a beta-3-adrenergic receptor agonist so that both exert physiological activity during an overlapping time period, wherein the beta-3-adrenergic receptor agonist is administered at a daily dosage ranging from about 10 mg to about 20 mg.
2. The method of claim 1 , wherein the method inhibits the urge to urinate in a human subject over an interval of about 4 hours to about 7 hours.
3. The method of claim 1 , wherein an antidiuretic effect is achieved over an interval of about two hours to no more than about six hours.
4. The method of claim 1 , wherein an antidiuretic effect is achieved over an interval of about four hours to no more than about seven hours.
5. The method of claim 1 , wherein desmopressin is administered transdermally, intradermally, or transmucosally across the oral or nasal mucosa.
6. The method of claim 1 , wherein desmopressin is administered transdermally or intradermally.
7. The method of claim 1 , wherein desmopressin is administered intranasally.
8. The method of claim 1 , wherein desmopressin is administered sublingually across the oral mucosa.
9. The method of claim 6 , wherein desmopressin is administered at a flux rate ranging from about 5 ng/hour to about 35 ng/hour.
10. The method of claim 6 , wherein desmopressin is administered at a flux rate ranging from about 5 ng/hour to about 15 ng/hour.
11. The method of claim 1 , wherein the beta-3-adrenergic receptor agonist is amibegron, fasobegron, mirabegron, ritobegron, solabegron, BRL-37344, CL-316,243, GS-332, KRP-204, L-796568, or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the beta-3-adrenergic receptor agonist is mirabegron.
13. The method of claim 1 wherein the formulation is administered intranasally.
14. The method of claim 1 , wherein the administering achieves in the subject a blood plasma concentration of desmopressin that does not exceed 15 pg/mL.
15. The method of claim 1 , wherein the administering achieves in the subject a blood plasma concentration of desmopressin in the range of about 0.5 pg/mL to about 5 pg/mL.
16. The method of claim 1 , wherein the administering achieves in the subject a blood plasma concentration of desmopressin in the range of about 0.5 pg/mL to about 2.5 pg/mL.